Ningbo Menovo Pharm Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 2.69%

Ningbo Menovo Pharm Co Ltd (603538) has an Asset Resilience Ratio of 2.69% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 603538 total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥127.52 Million
≈ $18.66 Million USD Cash + Short-term Investments

Total Assets

CN¥4.75 Billion
≈ $694.81 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2011–2024)

This chart shows how Ningbo Menovo Pharm Co Ltd's Asset Resilience Ratio has changed over time. See Ningbo Menovo Pharm Co Ltd book value and equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Ningbo Menovo Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Ningbo Menovo Pharm Co Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥127.52 Million 2.69%
Total Liquid Assets CN¥127.52 Million 2.69%

Asset Resilience Insights

  • Limited Liquidity: Ningbo Menovo Pharm Co Ltd maintains only 2.69% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Ningbo Menovo Pharm Co Ltd Industry Peers by Asset Resilience Ratio

Compare Ningbo Menovo Pharm Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
Drug Manufacturers - Specialty & Generic 43.05%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
Drug Manufacturers - Specialty & Generic 1.96%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Guobang Pharma Ltd
SHG:605507
Drug Manufacturers - Specialty & Generic 8.47%

Annual Asset Resilience Ratio for Ningbo Menovo Pharm Co Ltd (2011–2024)

The table below shows the annual Asset Resilience Ratio data for Ningbo Menovo Pharm Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 3.32% CN¥154.44 Million
≈ $22.60 Million
CN¥4.65 Billion
≈ $680.62 Million
-2.75pp
2023-12-31 6.07% CN¥268.65 Million
≈ $39.31 Million
CN¥4.42 Billion
≈ $647.30 Million
+1.15pp
2022-12-31 4.92% CN¥217.38 Million
≈ $31.81 Million
CN¥4.42 Billion
≈ $646.71 Million
-4.36pp
2021-12-31 9.28% CN¥371.38 Million
≈ $54.34 Million
CN¥4.00 Billion
≈ $585.54 Million
+4.93pp
2020-12-31 4.35% CN¥133.14 Million
≈ $19.48 Million
CN¥3.06 Billion
≈ $448.17 Million
+0.50pp
2019-12-31 3.85% CN¥100.60 Million
≈ $14.72 Million
CN¥2.61 Billion
≈ $382.51 Million
-12.80pp
2017-12-31 16.65% CN¥252.00 Million
≈ $36.88 Million
CN¥1.51 Billion
≈ $221.50 Million
+16.61pp
2012-12-31 0.04% CN¥350.50K
≈ $51.29K
CN¥831.58 Million
≈ $121.69 Million
-0.43pp
2011-12-31 0.48% CN¥3.37 Million
≈ $493.82K
CN¥709.97 Million
≈ $103.89 Million
--
pp = percentage points

About Ningbo Menovo Pharm Co Ltd

SHG:603538 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.01 Billion
CN¥13.77 Billion CNY
Market Cap Rank
#6227 Global
#1366 in China
Share Price
CN¥62.46
Change (1 day)
-4.35%
52-Week Range
CN¥13.71 - CN¥65.30
All Time High
CN¥65.30
About

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company's products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal t… Read more